{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:30:38Z","timestamp":1793496638998,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clinre.2026.102947","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:14:36Z","timestamp":1792538076000},"page":"102947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-response profiles in incretin and multi-agonist obesity pharmacotherapy"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7619-523X","authenticated-orcid":false,"given":"Mahdi","family":"Yousefian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0839-9779","authenticated-orcid":false,"given":"Maryam","family":"Baharmast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10431","key":"10.1016\/j.clinre.2026.102947_bib0001","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"issue":"10456","key":"10.1016\/j.clinre.2026.102947_bib0002","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0140-6736(24)01210-8","article-title":"Obesity in adults","volume":"404","author":"Lingvay","year":"2024","journal-title":"Lancet"},{"issue":"10322","key":"10.1016\/j.clinre.2026.102947_bib0003","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.clinre.2026.102947_bib0004","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"CMAJ"},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2026.102947_bib0005","first-page":"S166","article-title":"American Diabetes Association Professional Practice Committee for Diabetes 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.clinre.2026.102947_bib0006","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41573-026-01427-1","article-title":"The evolving landscape of obesity pharmacotherapy","volume":"25","author":"Petersen","year":"2026","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.clinre.2026.102947_bib0007","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/17407745251350289","article-title":"Dose-response characterization: a key to success in drug development","volume":"22","author":"Bretz","year":"2025","journal-title":"Clin Trials"},{"issue":"8","key":"10.1016\/j.clinre.2026.102947_bib0040","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.clinre.2026.102947_bib0041","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clinre.2026.102947_bib0042","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"10545","key":"10.1016\/j.clinre.2026.102947_bib0057","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0140-6736(26)00656-2","article-title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a randomised, double-blind, phase 3 trial","volume":"407","author":"Horn","year":"2026","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clinre.2026.102947_bib0060","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.clinre.2026.102947_bib0008","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.2337\/dbi21-0026","article-title":"Treatment of type 2 diabetes and obesity on the basis of the Incretin System: the 2021 Banting Medal for Scientific Achievement Award Lecture","volume":"70","author":"Holst","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.clinre.2026.102947_bib0009","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.clinre.2026.102947_bib0010","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.clinre.2026.102947_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.clinre.2026.102947_bib0012","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102947_bib0013","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endrev\/bnz002","article-title":"Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists\u202f=\u202fantagonists?","volume":"41","author":"Killion","year":"2020","journal-title":"Endocr Rev"},{"issue":"17","key":"10.1016\/j.clinre.2026.102947_bib0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"209","key":"10.1016\/j.clinre.2026.102947_bib0016","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.clinre.2026.102947_bib0018","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of Glucagon","volume":"97","author":"Muller","year":"2017","journal-title":"Physiol Rev"},{"issue":"21","key":"10.1016\/j.clinre.2026.102947_bib0019","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.3390\/ijms20215407","article-title":"Glucagon Regulation of Energy Expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.clinre.2026.102947_bib0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MED.0000000000000716","article-title":"Long-acting amylin analogues for obesity","volume":"29","author":"Mathiesen","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.clinre.2026.102947_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101109","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","volume":"46","author":"Sonne","year":"2021","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"Controlled trial of 3.0 mg of Liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clinre.2026.102947_bib0023","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"10.1016\/j.clinre.2026.102947_bib0024","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dom.12639","article-title":"Exposure-response analyses of liraglutide 3.0 mg for weight management","volume":"18","author":"Wilding","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.clinre.2026.102947_bib0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40262-016-0410-7","article-title":"Liraglutide 3.0 mg for weight management: a population pharmacokinetic analysis","volume":"55","author":"Overgaard","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"9701","key":"10.1016\/j.clinre.2026.102947_bib0026","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinre.2026.102947_bib0027","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"10148","key":"10.1016\/j.clinre.2026.102947_bib0028","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clinre.2026.102947_bib0029","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.clinre.2026.102947_bib0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.clinre.2026.102947_bib0031","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.clinre.2026.102947_bib0032","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clinre.2026.102947_bib0033","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clinre.2026.102947_bib0034","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102947_bib0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.clinre.2026.102947_bib0036","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1016\/j.clinre.2026.102947_bib0037","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"10403","key":"10.1016\/j.clinre.2026.102947_bib0038","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clinre.2026.102947_bib0039","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clinre.2026.102947_bib0043","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.clinre.2026.102947_bib0044","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/dom.15211","article-title":"A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity","volume":"25","author":"Strathe","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"10160","key":"10.1016\/j.clinre.2026.102947_bib0046","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"10295","key":"10.1016\/j.clinre.2026.102947_bib0047","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinre.2026.102947_bib0048","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"issue":"10300","key":"10.1016\/j.clinre.2026.102947_bib0049","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.clinre.2026.102947_bib0050","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): an open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinre.2026.102947_bib0051","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.clinre.2026.102947_bib0052","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinre.2026.102947_bib0061","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J Endocr Soc"},{"issue":"10402","key":"10.1016\/j.clinre.2026.102947_bib0053","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2026.102947_bib0054","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0056","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinre.2026.102947_bib0058","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/psp4.13099","article-title":"Population pharmacokinetics of the GIP\/GLP receptor agonist tirzepatide","volume":"13","author":"Schneck","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102947_bib0059","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/cpt.3750","article-title":"A pharmacometric method for quantitative determination of improvement in body composition and characterization of the exposure-response relationship during treatment of obesity with tirzepatide","volume":"118","author":"Chigutsa","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.clinre.2026.102947_bib0062","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"10317","key":"10.1016\/j.clinre.2026.102947_bib0063","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinre.2026.102947_bib0069","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clinre.2026.102947_bib0072","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"issue":"10403","key":"10.1016\/j.clinre.2026.102947_bib0064","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinre.2026.102947_bib0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinre.2026.102947_bib0066","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clinre.2026.102947_bib0067","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S2213-8587(25)00402-4","article-title":"Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity (REDEFINE 5): a randomised, double-blind, phase 3 trial","volume":"14","author":"Yamauchi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102947_bib0068","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-8587(26)00125-7","article-title":"Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a randomised, phase 3 trial","volume":"14","author":"Buse","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10401","key":"10.1016\/j.clinre.2026.102947_bib0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clinre.2026.102947_bib0075","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102947_bib0076","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMoa2600751","article-title":"Survodutide once weekly for the treatment of adults with obesity","volume":"395","author":"le Roux","year":"2026","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clinre.2026.102947_bib0071","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinre.2026.102947_bib0073","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/s41591-026-04386-7","article-title":"Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial","volume":"32","author":"Aronne","year":"2026","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.clinre.2026.102947_bib0074","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clinre.2026.102947_bib0077","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.clinre.2026.102947_bib0078","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist Danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.clinre.2026.102947_bib0079","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule GLP-1 receptor agonist danuglipron for type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 study comparing different dose-escalation schemes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"10499","key":"10.1016\/j.clinre.2026.102947_bib0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clinre.2026.102947_bib0081","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clinre.2026.102947_bib0082","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S2213-8587(25)00141-X","article-title":"Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Ji","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinre.2026.102947_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156494","article-title":"Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond","volume":"177","author":"Muzurovic","year":"2026","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0083","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Martinez","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12020-025-04494-3","article-title":"Exploring the rates of gastrointestinal adverse effects among five GLP-1 receptor agonists: a systematic review and meta-analysis of randomized controlled trials","volume":"91","author":"Joy","year":"2026","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.clinre.2026.102947_bib0084","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.clinre.2026.102947_bib0086","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/oby.24331","article-title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.clinre.2026.102947_bib0087","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/oby.70058","article-title":"Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.clinre.2026.102947_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103796","article-title":"Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression","volume":"93","author":"Budini","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.clinre.2026.102947_bib0089","article-title":"Post-cessation weight regain after weight management medications: a systematic review and meta-analysis","volume":"18","author":"Patel","year":"2026","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.clinre.2026.102947_bib0085","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","volume":"66","author":"Tschop","year":"2023","journal-title":"Diabetologia"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:23:09Z","timestamp":1793496189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126001920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":91,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2210740126001920"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102947","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-response profiles in incretin and multi-agonist obesity pharmacotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102947"}}